24 results about "Transdifferentiation" patented technology

A method of direct transdifferentiation of somatic cells into other somatic cells may be convenient and still have good reproducibility, excellent production efficiency, and short performed time. Methods for direct transdifferentiation of somatic cells into other somatic cells may include: (a) introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into other somatic cells.

The invention belongs to the technical field of biology, and discloses a serum-free culture medium and application thereof in obtaining nerve cells through embryo fibroblast transdifferentiation. The serum-free culture medium consists of a basic culture medium, a protein additive and cell culture auxiliary components, the protein additive consists of transferrin, a leukemia inhibition factor and a basic fibroblast growth factor; the final concentration of the transferrin is 5 ng / mL-30 ng / mL, the final concentration of the leukemia inhibition factor is 50 ng / mL-150 ng / mL, and the final concentration of the basic fibroblast growth factor is 10 ng / mL-25 ng / mL. The serum-free culture medium can promote the conversion speed of transdifferentiation of fibroblasts into nerve cells, can significantly improve the transdifferentiation efficiency, and can improve the cell survival rate of transdifferentiation of mouse embryo fibroblasts into nerve cells.

The present application belongs to the field of biomedical technology, and particularly relates to a cell-derived extracellular matrix and a preparation method and application of a cell culture plate coated with the cell-derived extracellular matrix. The present application cultures human astrocytes in a cell culture plate, and makes the human astrocytes secrete extracellular matrix. After the human astrocytes are added into a cell lysate for cell removal treatment, nucleic acid fragmentation treatment is performed to obtain the cell-derived extracellular matrix. The present application has relatively simple operation, short time period, and can realize batch production of extracellular matrix without external virus carrying and stable components. The obtained cell-derived extracellular matrix is resistant to storage, has good stability, is highly similar to a natural brain environment when coated on a cell culture plate, has good biocompatibility with cells, can be applied to tissue repair and regeneration as an ideal biomedical material, can regulate the progress and efficiency of human dermal fibroblast HDF transdifferentiation into neurons, and can obtain in-vitro survival neurons.

Provided is a method for production by direct transdifferentiation of somatic cells into another somatic cells which is convenient, has good reproducibility, is excellent in production efficiency, and is performed in a short period of time. The method for production by direct transdifferentiation of somatic cells into another somatic cells comprises: (a) a step of introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) a step of culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into another somatic cells.

The present application provides a method for in vitro purified corneal limbal stem cells to be transdifferentiated into lens spherules, specifically, the present application inoculates corneal limbal stem cells onto a culture plate containing a Matrigel glue layer, and cultures the corneal limbal stem cells in a culture system containing Y-27632 additives in LSCM culture solution, so that lens spherule organoids can be obtained. The method of the present application can realize the rapid transdifferentiation of corneal limbal stem cells into lens spherules, so that they can be implanted into the capsular bag as seed cells for in situ regeneration of the lens.

The invention relates to the field of biological medicine, in particular to a si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of the si-RNA composition. The si-RNA composition comprises a si-RNA (Ribonucleic Acid) aiming at a gene Huwe1, a si-RNA aiming at a gene Ltbp3, a si-RNA aiming at a gene Dysf and a si-RNA aiming at a gene Hivep3. The HLDH (Huwe1, Ltbp3, Dysf and Hive3) combined knockout can be used for successfully inducing the transformation of fibroblasts into endothelial cells in an in-vitro ischemia and hypoxia state. A carrier containing shRNA capable of expressing and generating the si-RNA composition is delivered into the heart, so that cardiac fibroblasts undergo transdifferentiation in vivo and participate in angiogenesis, and therefore, increase of fibrosis area and adverse ventricular remodeling after myocardial ischemia are limited through ways such as fibrosis remodeling, the heart function is retained, and myocardial ischemia is improved and repaired.

Compositions and methods are described herein for transdifferentiation of multipotent stromal cells into cells that can express insulin.

The application belongs to the technical field of biotechnology, and specifically discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and provides overexpression of a neurogenesis-promoting transcription factor and knockdown of an inducible hindering factor, which are expected to be effective methods for improving transdifferentiation efficiency and generating more newborn neurons, and thus are widely applied to treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases and traumatic diseases of the central nervous system.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

The invention discloses an induction culture medium for inducing fibroblasts to transdifferentiate into nucleus pulposus cells and application of the induction culture medium, and belongs to the technical field of cytobiology and regenerative medicine. The induction culture medium comprises a basic culture medium and an induction composition, can be used for realizing 2D / 3D transdifferentiation of fibroblasts into nucleus pulposus cells, and meets the requirements of different application scenes. Meanwhile, the invention further provides an amplification culture medium, a technical system for forming a 3D (three-dimensional) organoid through amplification of the amplification culture medium is provided, and the method has important significance in promoting cell therapy of the intervertebral disc degenerative change.

The present application relates to the field of cell reprogramming, and in particular to a method for inducing fibroblast transdifferentiation into kidney epithelial cells by using a double-stranded retrovirus vector combined with a double selection antibiotic screening strategy. The present application first applies a double-stranded retrovirus vector, and adds a Puromycin and Blasticin double-antibiotic screening strategy, to induce four transcription factors Hnf1beta, Emx2, Pax8 and Hnf4alpha to reprogram embryonic fibroblasts into kidney tubular epithelial cells within two weeks. The establishment of the technical system of the present application will provide strong technical support for obtaining kidney tubular epithelial cells in vitro.

The invention belongs to the field of biotechnology medicine, and particularly relates to a method for improving the induction efficiency of transdifferentiation from astrocytes to neurons, which comprises the following steps: preparing primary astrocytes: separating cortical tissues to prepare a cell suspension, and culturing and purifying to obtain the astrocytes. And transdifferentiation induction: transducing the astrocytes by using lentivirus, changing a differential medium and adding BDNF for culture to promote the astrocytes to be transdifferentiated into mature neurons. Animal model and targeted induction: establishing a cerebral infarction model, and injecting AAV-Neurog2-Pax6 virus into a focus area to realize specific transdifferentiation of astrocytes; the method comprises the following steps: performing in-vivo induction and sample treatment: performing perfusion fixation, dehydration, embedding and freezing slicing after taking materials, retaining the integrity of transdifferentiated cells, and performing overexpression on Neurog2 and Pax6 to realize transdifferentiation of the astrocytes to neurons and improve the induction efficiency of transdifferentiation of the astrocytes to the neurons.

The invention provides application of an IP receptor stimulant in preparation of a medicine for treating lung injury, and relates to the technical field of biological medicine. Transdifferentiation of alveolar II-type epithelial cells to I-type epithelial cells after lung injury is realized by utilizing selepag and other IP receptor agonists, and the scheme not only can relieve lung tissue inflammation and fibrosis degree induced by bleomycin and other factors, but also can reduce the death rate of model animals and improve lung function prognosis. Meanwhile, the used IP receptor stimulant part is a clinically mastered drug, so that the safety is higher, the selectivity is good, and a new effective way and a new drug development direction are provided for the treatment of lung injury and related fibrosis diseases.

The application relates to the technical field of medical information processing, and discloses a tumor prognosis model training method and system based on transdifferentiation related genes, which comprises the following steps: step 1, acquiring gene expression, clinical characteristics and survival follow-up data, and extracting transdifferentiation gene expression data; step 2, determining transdifferentiation gene normalization relative order values; step 3, determining a starting plasticity end index, a blood vessel acquisition end index and a transdifferentiation direction index; step 4, determining a microenvironment consequence index, coupling strength and a synergistic enhancement item; step 5, performing consistency screening to obtain a stable transdifferentiation characteristic gene set; step 6, performing constraint training to obtain a prognosis model weight parameter and a trained tumor prognosis model; and step 7, calculating a final prognosis risk score, determining an optimal risk classification threshold, and obtaining a risk stratification result. The application realizes the generation of a tumor patient prognosis risk score and a risk stratification result.

This application discloses the application of Bcl11a in the preparation of drugs for nerve injury repair, belonging to the field of biomedical technology. The nerve injury is a central nervous system injury. Overexpression of Bcl11a promotes the transdifferentiation of an intermediate state astrocyte in the cerebral cortex into pyramidal neurons. Using Bcl11a as a molecular intervention target, targeting the M1 motor area of ​​the cerebral cortex, overexpression of Bcl11a in astrocyte subset 2 promotes the reprogramming of astrocytes into pyramidal neurons, promoting the repair of central nervous system injury. Using spatial transcriptome sequencing technology and single-cell sequencing technology, the dynamic trajectory between astrocytes and pyramidal cells was depicted, supporting the transformation of an intermediate transitional state astrocyte in the cortex into pyramidal cell subset 3 after spinal cord injury, indicating that Bcl11a and Zmart4 are key transcription factors in the connection between pyramidal cells and glial cells.

The present application provides a method for directly transdifferentiating spermatogonial stem cells (SSCs) into neural stem cell-like cells (iNSCs). The iNSCs have proliferative activity, can be stably subcultured in vitro, and have the potential to differentiate into other neural cells such as neurons, astrocytes and oligodendrocytes. The method of the present application has high efficiency, can obtain more iNSCs in a relatively short period in vitro, and can obtain iNSCs with high purity, wherein the double positive rate of Nestin and Pax6 is more than 95%.

The invention provides a method for transdifferentiating corneal limbal stem cells purified in vitro into crystalline lens bodies, and particularly, the method comprises the following steps: inoculating the corneal limbal stem cells onto a culture plate containing a Matrigel glue layer, and culturing the corneal limbal stem cells in a culture system of an LSCM culture solution containing a Y-27632 additive, so that crystalline lens body organs can be obtained. According to the method disclosed by the invention, the corneal limbus stem cells can be quickly transdifferentiated into crystalline lens bodies, so that the corneal limbus stem cells can be implanted into a capsular bag to serve as seed cells for in-situ regeneration of crystalline lenses.

The present application relates to the field of cell biology and cell therapy, in particular to targets and small molecule compounds for neural cell transdifferentiation. Specifically, the present application relates to a method of transdifferentiating astrocytes into other types of neurons, the method comprising contacting a plurality of astrocytes with a gamma secretase inhibitor and culturing the astrocytes. The present application also relates to the cell population obtained by this method and its therapeutic use.

The invention provides a construction method and application of a bifluorescence reporter gene animal model for tracking transdifferentiation from airway cilia cells to mucous cells. A transgenic animal model capable of specifically and permanently marking and tracking airway ciliary cell fate transformation is constructed by utilizing a Cre-LoxP gene recombinase system and combining with double promoters and double fluorescence reporter genes. In the progeny, normal cilia cells only express GFP (green). When the cell starts to express MUC5AC under external stimulation (such as PM2.5 and allergen), the existing Cre recombinase in the cell nucleus can recognize and cut off the loxP-Stop-loxP sequence at the downstream of the MUC5AC gene, so that the expression of the RFP gene is started. Finally, mucus-cilia cells obtained by transdifferentiation of cilia cells can simultaneously express GFP (green fluorescent protein) and RFP (yellow), or only express RFP (red) after completely losing cilia cell characteristics. The irreversible color conversion provides a definite evidence for the'provenance and today 'of the cells.

The present invention relates to the technical field of biomedicine, and specifically provides an empowered mesenchymal stem cell, an empowered mesenchymal stem cell composition, and use thereof in the preparation of a drug for treating organ dysfunction. The empowered mesenchymal stem cell is obtained by treating human mesenchymal stem cells with ingenol HEP14. The empowered mesenchymal stem cell composition comprises the empowered mesenchymal stem cell and an HEP14 / PLGA microsphere having a high HEP14 loading capacity and a long-acting HEP14 sustained release prepared by using poly(lactic-co-glycolic acid) (PLGA) as a carrier. The empowered mesenchymal stem cell has the effects of enhancing the viability and stemness of mesenchymal stem cells, resisting tissue fibrosis, promoting tissue angiogenesis, and promoting tissue regeneration and functional recovery. The combined use of the empowered mesenchymal stem cell and the HEP14 / PLGA microsphere enhances the effects of retention and transdifferentiation of the empowered mesenchymal stem cell in tissues, thereby further enhancing the function of the empowered mesenchymal stem cell and the use thereof in the field of regenerative medicine.

The invention discloses a transdifferentiation immunologic function of nucleated red blood cells of an ARDS patient and application of the transdifferentiation immunologic function, and belongs to the field of biomedicine. The first aspect of the invention relates to application of a reagent for detecting reticulocyte damage and / or a reagent for detecting T cell markers carried by nucleated red blood cells in preparation of a kit for diagnosing acute respiratory distress syndrome. On the second aspect, the invention relates to a method for detecting differentiation of nucleated red blood cells, which comprises the following steps: screening nucleated red blood cells which grow later; and detecting and / or counting nucleated red blood cells with T cell markers in nucleated red blood cells with later development. The invention discloses the differentiation phenomenon of nucleated red blood cells, and the nucleated red blood cells can be applied to the research of the ARDS process and the diagnosis of ARDS.

The application belongs to the technical field of biomedicine, and specifically discloses a kind of enabled mesenchymal stem cells, enabled mesenchymal stem cell composition and its application in preparation treatment organ dysfunction drug, and the enabled mesenchymal stem cells are obtained by treating human mesenchymal stem cells with a kind of halogenated salicylic alcohol HEP14, and the enabled mesenchymal stem cell composition includes the enabled mesenchymal stem cells and HEP14 / PLGA microspheres with high HEP14 load and long-acting HEP14 sustained release prepared by using polylactic acid-hydroxyacetic acid copolymer (PLGA) as a carrier.The enabled mesenchymal stem cells of the application have the effects of strengthening mesenchymal stem cell survival viability and stemness, resisting tissue fibrosis, promoting tissue angiogenesis, promoting tissue regeneration and functional recovery;the combined application of the enabled mesenchymal stem cells and HEP14 / PLGA microspheres strengthens the retention and transdifferentiation of the enabled mesenchymal stem cells in the tissue, so the function of the enabled mesenchymal stem cells and the application in the field of regenerative medicine are further strengthened.

Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.

The present invention relates to a composition for inducing transdifferentiation through oligomerization of CtBPs, and uses of stem cells treated therewith. Since the compounds of the present invention can induce transdifferentiation of adult stem cells into neural progenitor cells by regulating the oligomerization of CtBPs, the compounds can be used for inducing oligomerization or transdifferentiation of CtBPs. In addition, since ciNSC5 derived from transdifferentiation exhibits remarkable therapeutic effects in an ALS mouse model, an MS mouse model, a PD rat model, and a chronic spinal cord injury rat model, ciNSC5 can be used as a cellular therapeutic agent.